dpp4i and glp 1 agonist Role of DPP-4 Inhibitors in Clinical Practice GLP-1 receptor agonist versus DPP-4
Description
The 2025 Prohibited List and WADAs explanatory note on the modifications can be found here

The REWIND trial suggested that dulaglutide might be effective for both primary and secondary cardiovascular prevention in individuals with T2DM (254)

UK 7.3.2.1

Because weight-loss medications like Ozempic or Wegovy dramatically slow down your digestive system, adding this heavy mass creates a literal logjam

Semaglutide: nonarteritic anterior ischemic optic neuropathy in the FDA adverse event reporting system: a disproportionality analysis

Forecasting Framework and Scenario Modelling Market forecasts were developed using a combination of time-series modelling, adoption curve analysis, and driver-based forecasting tools
